Rhumbline Advisers Merrimack Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 01, 2024	SELL	$14.68 - $15.13 $162,052 - $167,020	-11,039 Reduced 81.66%	2,480 $37,000
Q1 2024 May 09, 2024	SELL	$13.06 - $15.0 $5,641 - $6,480	-432 Reduced 3.1%	13,519 $199,000
Q4 2023 Feb 08, 2024	BUY	$12.02 - $13.41 $865 - $965	72 Added 0.52%	13,951 $187,000
Q3 2023 Nov 09, 2023	BUY	$11.6 - $12.52 $15,230 - $16,438	1,313 Added 10.45%	13,879 $171,000
Q2 2023 Aug 08, 2023	BUY	$12.02 - $13.07 $151,043 - $164,237	12,566 New	12,566 $154,000
Q2 2018 Aug 06, 2018	SELL	$3.86 - $7.61 $45,922 - $90,536	-11,897 Closed	0 $0
Q1 2018 May 02, 2018	SELL	$6.24 - $9.15 $1,747 - $2,562	-280 Reduced 2.3%	11,897 $96,000
Q4 2017 Feb 09, 2018	SELL	$7.99 - $11.87 $19,831 - $29,461	-2,482 Reduced 16.93%	12,177 $125,000
Q3 2017 Nov 06, 2017	BUY	$9.13 - $11.72 $133,836 - $171,803	14,659	14,659 $213,000

Others Institutions Holding MACK

# of Institutions

2

Shares Held

349

Call Options Held

0

Put Options Held

0

About MERRIMACK PHARMACEUTICALS INC

Ticker MACK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,410,200
Market Cap $203M
Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

More about MACK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.